OcellO Joins Crown Bioscience

I am pleased to announce that OcellO B.V. has been acquired by Crown Bioscience Inc (CrownBio), a JSR Life Sciences Company.

OcellO was launched in 2011 with a focus on compound testing services in cultured tissues combining deep image analysis. Beginning with oncology models using cell lines, we developed our technology platform to include organoids and primary patient tissues, extending to immuno-oncology, inflammation, and cystopathic indications. Over the last ten years, our growth was built on our commitment to our customers and our core principles of innovation and quality. Our success has been, in no small way, directly related to joint development of models to address specific customer need and the successes and scientific discoveries that our customers have achieved. Thank you for your part in helping us get to where we are now.

I anticipate that upon hearing this news, you will have immediate questions. I want to assure you that for the immediate future there will be no changes to your experience working with OcellO. Our laser focus has always been and will continue to be on our customers.

  • You will continue to work with the same OcellO team
  • OcellO will continue to be led by the same team, driving the development of in vitro offerings at CrownBio
  • Our existing contracts, MSAs and pricing models, will remain in place
  • Our service offerings will continue without interruption.
  • We will continue to operate from our current Leiden location

Joining CrownBio will make our company stronger, more competitive, and will have a particular impact on the breadth of in vitro models that we can offer and develop, including organoids for a broad range of tumour types. Over the coming months, we will be working with our new colleagues to combine OcellO’s in vitro expertise into CrownBio’s service portfolios.

We value our partnership and are grateful to you for giving us the opportunity to fulfill your study needs. We hope that you will continue to place your trust in OcellO in its new place in CrownBio. We are confident that our new affiliation with CrownBio will bring many more exciting opportunities for you and for us.

— Leo Price, PhD, Senior Vice President, In Vitro and Head of Crownbio Netherlands